Results 191 to 200 of about 101,642 (212)

Monoallelic POLR3A Variants Cause Early‐Onset Peripheral Neuropathy

Annals of Neurology, EarlyView.
Objective Biallelic variants in genes encoding the RNA polymerase III complex (Pol III) cause a spectrum of neurological disorders primarily affecting the central nervous system. Monoallelic variants have been reported in the POLR3B subunit only, associated with neurodevelopmental disorder, epilepsy, and peripheral neuropathy.
Luiza L. P. Ramos, Jevin M. Parmar, Robin Wijngaard, Bianca R. Grosz, Tamas Lazar, Ligia Mateiu, Steve Vucic, Kishore R. Kumar, Dennis Yeow, Laura I. Rudaks, Lonneke de Boer, Annemarie de Vreugd, David A. Koolen, Thatjana Gardeitchik, Anita Cairns, Krishnan Iyengar, Fernando Kok, Fernanda Barbosa Figueiredo, Alzira Alves de Siqueira Carvalho, Luiz S. Mageste Barbosa, Rodrigo Rezende Arantes, Tyler Rehbein, Jordan E. Bontrager, Elizabeth P. Wood, Janet E. Sowden, Gavin Monahan, Meutia Kumaheri, Ivy Cuijt, Melina Ellis, Gonzalo Perez‐Siles, Elyshia McNamara, Ronald van Beek, Celine B. Meijers, Ivaylo Tournev, Stephan Zuchner, Shoshana J. Wodak, Clara D. M. van Karnebeek, Nigel Laing, Liana N. Semcesen, David A. Stroud, David N. Herrmann, Velina Guergueltcheva, Marina L. Kennerson, Machteld M. Oud, Gianina Ravenscroft, Ayse Candayan, Albena Jordanova   +46 more
wiley   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

An Ultrahigh‐Field‐Tailored T1–T2 Dual‐Mode MRI Contrast Agent for High‐Performance Vascular Imaging

Advanced Materials, 2021
Zeyu Liang, Fangyuan Li, Ruiliang Bai
exaly  

A novel amino phosphonate-coated magnetic nanoparticle as MRI contrast agent

Applied Surface Science, 2021
Luelc Souza da Costa, Rafael M Freire, Juliano C Denardin   +2 more
exaly  

A Facile Synthesis, In vitro and In vivo MR Studies of d-Glucuronic Acid-Coated Ultrasmall Ln2O3 (Ln = Eu, Gd, Dy, Ho, and Er) Nanoparticles as a New Potential MRI Contrast Agent

ACS Applied Materials & Interfaces, 2011
Krishna Kattel, Ja Young Park, Badrul Alam Bony   +2 more
exaly  

T1 and T2 Dual-Mode MRI Contrast Agent for Enhancing Accuracy by Engineered Nanomaterials

ACS Nano, 2014
Tae-Hyun Shin, Hsian-Rong Tseng, Seokhwan Yun   +2 more
exaly  

Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection

Biomaterials, 2014
Yu-Jen Chen, Shou-Cheng Wu, Shey-Cherng Tzou   +2 more
exaly  

Design and characterization of a new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide

Magnetic Resonance in Medicine, 2007
Guanshu Liu, Mark D Pagel
exaly  

Gadolinium(III) chelated conjugated polymer as a potential MRI contrast agent

Polymer, 2010
Qingling Xu, Minghui Yu, Fude Feng
exaly  

Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent

Journal of Drug Targeting, 2011
Zhijin Chen, Dexin Yu, Chunxi Liu
exaly